Intermittent Claudication Market Report Examines Industry Trends, Growth Drivers And Future Outlook

Exploring the Future Growth of the Intermittent Claudication Market

The intermittent claudication market is set to experience significant expansion over the coming years. Forecasts indicate that by 2030, the market will reach a valuation of $17.98 billion, growing at a compound annual growth rate (CAGR) of 5.9%. This upward trajectory is largely driven by heightened awareness of peripheral artery disease symptoms, an increasing preference for less invasive vascular treatment options, ongoing progress in drug therapies, greater uptake of home-based disease management techniques, and improvements in screening and diagnostic methods. Key trends shaping the market outlook include a stronger emphasis on early diagnosis, wider use of combination drug therapies, increased popularity of minimally invasive revascularization procedures, broader implementation of supervised exercise therapy programs, and enhanced patient education around disease management.

The intermittent claudication market size has grown strongly in recent years. It will grow from $13.51 billion in 2025 to $14.31 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to rising prevalence of peripheral artery disease, increasing aging population, high incidence of smoking-related vascular disorders, growth in cardiovascular disease burden, expanded availability of vascular intervention procedures.

Download a free sample of the intermittent claudication market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Companies Influencing the Intermittent Claudication Industry

The intermittent claudication market features several important players actively shaping its development. Leading companies in this sector include Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, Alkem Laboratories, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, and Enomark Pharma.

View the full intermittent claudication market report:
https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Strategic Acquisitions Strengthening Market Positions

In a notable move in April 2023, Abbott Laboratories, a US-based healthcare firm, acquired Cardiovascular Systems Inc. for $890 million. This acquisition is aimed at expanding Abbott's portfolio of vascular devices by integrating Cardiovascular Systems Inc.'s state-of-the-art technologies designed to treat peripheral artery disease (PAD) and coronary artery conditions. The deal bolsters Abbott's presence in the cardiovascular sector and enhances patient care through advanced minimally invasive treatment options. Cardiovascular Systems Inc., based in the US, is known for delivering innovative medical devices specifically targeting PAD, including intermittent claudication therapies.

Innovations Driving Treatment Advances in the Intermittent Claudication Market

Companies in this arena are increasingly focusing on minimally invasive endovascular technologies to improve treatment effectiveness, procedural success rates, and patient recovery experiences. One such innovation is the development of percutaneous bypass systems, which create endovascular bypass routes using specialized stent grafts and catheters. These systems enable restoration of blood flow across extensive arterial blockages, reduce the need for open surgical bypass, and promote quicker recovery.

For example, in June 2023, Endologix LLC, a US-based medical device company specializing in vascular therapies, gained FDA approval for its DETOUR System. This minimally invasive percutaneous bypass solution targets complex and long superficial femoropopliteal lesions in patients suffering from peripheral artery disease. The system incorporates the TORUS stent graft, a novel endovascular technique capable of addressing long-segment occlusions. By improving blood flow restoration and reducing procedural complications, the DETOUR System broadens treatment possibilities for those with symptomatic PAD and intermittent claudication.

Segmentation Overview of the Intermittent Claudication Market

The report segments the intermittent claudication market into the following categories:

1) By Type: Medication Therapies, Revascularization
2) By Route of Administration: Parenteral Route, Oral Route, Other Routes of Administration
3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Further subcategories include:

- Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline
- Revascularization Procedures: Angioplasty, Stenting, Bypass Surgery, Endarterectomy

This detailed segmentation offers a comprehensive understanding of the market's structure and the varied treatment options available to patients suffering from intermittent claudication.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.